Biogen's (BIIB) Samsung Sale Frees Up Capital for Strategic Alternatives, Expect Uptick in Stock - Stifel
Tweet Send to a Friend
Needham & Company analyst Ami Fadia reiterated a Buy rating and $292.00 price target on Biogen (NASDAQ: BIIB), following company's ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
